ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: A study of 401 cases

Histopathology

Volumn 62, Issue 7, 2013, Pages 976-985

  Mhawech Fauceglia, Paulette ^a   Yan, Li ^b   Liu, Song ^b   Pejovic, Tanja ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Differential diagnosis; Endometrial adenocarcinoma; Immunomarkers; Tissue microarray

Indexed keywords

ESTROGEN RECEPTOR; INTESTINAL TREFOIL FACTOR; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPRODUCIBILITY; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

LOTUS;

EID: 84877924765     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12096     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59; 225-249.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
3. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer Control 2009; 16; 8-13.
4. Kitchener HC, Trimble EL. Endometrial cancer state of the science meeting. Int. J. Gynecol. Cancer 2009; 19; 134-140.
5. Naumann RW. Uterine papillary serous carcinoma: state of the state. Curr. Oncol. Rep. 2008; 10; 505-511.
6. Benito V, Lubrano A, Arencibia O etal. Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. Int. J. Gynecol. Cancer 2009; 19; 1364-1369.
7. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubick-Huch RA, Tavassoli FA. Tumors of the uterine corpus. In Tavassoli FA, Devilee P eds. World Health Organization classification. Lyon: IARC Press, 2003; 217-257.
8. Zaino RJ. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int. J. Gynecol. Pathol. 2008; 28; 1-9.
9. Hamilton CA, Cheung MK, Osann K etal. Uterine papillary serous and clear carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 2006; 94; 642-646.
10. Boruta DM, Gehrig PA, Groben PA etal. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 101; 2214-2221.
11. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Byle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol. 2004; 95; 593-596.
12. Cirisano FD Jr, Robboy SJ, Dodge RK etal. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol. 1999; 74; 385-394.
13. Cirisano FD Jr, Robboy SJ, Dodge RK etal. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol. Oncol. 2000; 77; 55-56.
14. Soslow RA, Bissonnette JP, Wilton A etal. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes; similar outcomes belie distinctive biologic differences. Am. J. Surg. Pathol. 2007; 31; 979-987.
15. Mhawech-Fauceglia P, Herrmann RF, Kesterson J, Izevbaye I, Lele S, Odunsi K. Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium. Eur. J. Surg. Oncol. 2010; 36; 1195-1201.
16. Silverberg SG. The endometrium. Pathologic principles and pitfalls. Arch. Pathol. Lab. Med. 2007; 131; 372-382.
17. Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int. J. Gynecol. Pathol. 2001; 20; 252-259.
18. Carcangiu ML, Chambers JT, Voynick IM etal. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am. J. Clin. Pathol. 1990; 944; 255-260.
19. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression. Hum. Pathol. 1998; 29; 551-558.
20. Soslow RA, Shen P, Chung MH, Isacson C, Baergen RN. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int. J. Gynecol. Pathol. 2000; 19; 329-334.
21. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2008; 19; 1091-1100.
22. Zheng W, Yi X, Fadare O etal. The oncofetal protein IMP3. A novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 2008; 32; 304-315.
23. Mhawech-Fauceglia P, Herrmann F, Rai H etal. IMP3 is a powerful immunomarker in distinguishing uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 2010; 133; 899-908.
24. Yamachika T, Werther JL, Bodian C etal. Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin. Cancer Res. 2002; 8; 1092-1099.
25. Bignotti E, Ravaggi A, Tassi RA etal. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br. J. Cancer 2008; 99; 768-773.
26. Risinger JI, Maxwell GL, Chandramouli VR etal. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003; 63; 6-11.
27. Mhawech P, Benz A, Greloz V etal. Down-regulation of 14-3-3σ in ovary, prostate, and endometrial canrcinomas is associated with CpG-methylation. Mod. Pathol. 2005; 18; 340-348.
28. Mhawech-Fauceglia P, Fischer G, Alvarez V, Ahmed A, Herrmann F. Predicting outcome in minimally invasive (T1A and T1B) urothelial bladder carcinoma using a panel of biomarkers; a high throughput tissue microarray analysis. BJU Int. 2007; 100; 1182-1187.
29. Shiao YH, Palli D, Caporaso NE etal. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol. Biomarkers Prev. 2000; 9; 631-633.
30. Allred DC, Bustamante MA, Daniel CO. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch. Surg. 1990; 125; 107-113.
31. Darvishian F, Hummer AJ, Thaler HT etal. Serous endometrial cancers that mimic endometrioid adenocarcinomas. A clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 2004; 28; 1568-1578.
32. Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 2010; 29; 343-350.
33. Neilson J, Christiansen J, Lykke-Andersen J etal. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol. 1999; 9; 1262-1270.
34. Li C, Zota V, Wonda BA etal. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod. Pathol. 2007; 20; 1263-1268.
35. Seib T, Blin N, Hilgert K etal. The three human trefoil genes TFF1, TFF2, and TFF3 are located within a region of 55 kb on chromosome 21q22.3. Genomics 1997; 20; 200-202.
36. Poulsom R, Hanby AM, Lalani E-N etal. Intestinal trefoil factor (TFF3) and pS2 but not spasmolytic polypeptides are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J. Pathol. 1997; 183; 30-38.
37. Mhawech-Fauceglia P, Wang D, Kesterson J etal. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PLOS One 2011; 6; e18066.